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Abstract 
Background: This Study was conducted to 
compare mean levels of quantitative PCR (RNA) of 
males and female Hepatitis C positive patients along 
with any disparity in responsiveness towards 
interferon therapy between males and females. 
Methods: This cross sectional analytical study was 
conducted from February 2015 to January 2016 at the 
Liver Centre of Holy Family Hospital, Rawalpindi, 
Pakistan. 204 patients of Hepatitis C, 104 males and 
100 females were selected through Simple Random 
Sampling. The data was collected from the records of 
the patients regarding gender, HCV load, 
Quantitative PCR (polymerase chain reaction) to 
interferon, past surgical and transfusion history.  
Results: Mean PCR of females was 4.57E6± 1.998E7 
IU whereas mean PCR of males was 3.04E6 
±8296048.199 and this difference was not statistically 
significant, (p=0.47). Among the males, 46.26% did 
not respond to the interferon treatment whereas 
those who responded were 34.69%. While among the 
females, 65.30% of did not respond to treatment and 
34.70% responded, with a statistically insignificant 
difference (p=0.2). 
Conclusion: HCV load is unequivocally 
distributed amongst males and females. Females 
emerged as better responders to conventional 
pegylated 2 alpha interferon therapy than males. 
Key Words: HCV, viral load, interferon, response, 
gender, Polymerase Chain Reaction. 
Introduction 
HCV load corresponds to the number of virus particles 
circulating in the blood serum. HCV load depends on 
being exposed to and then harbouring the HCV inside 
the body. It is not mere getting the virus inside your 
blood rather to have it nurturing in the serum due to 
inability to ward it off from the body. Poignancy for 
having HCV retained within the body correlates with 
sustainability of virus. The sustainable survival of 
HCV is related to non-responsiveness or reduced 
response to therapy, and presence or absence of 
certain inherent inhibitors of virus induced damage. 
HCV load thereby is born via reduced treatment 
response and dis-inhibition of viral replication and 
virus provoked damage, once HCV has penetrated the 
barriers. HCV load distribution between males and 
females attracts curious researches. HCV load is 
precariously heavier in men than in women whilst 
females emerging as better interferon responders. 
Gender has been rendered a milestone in defining 
innate tendency to eradicate HCV; the spontaneity 
with which females abate the HCV load is higher than 
in males. 1,2 Premenopausal females are better 
candidates for interferon  responsiveness owing to 
their lower BMI than men and young age thereby, 
many women are spared of HCV load despite getting 
infected.3,4 Nevertheless, there is inevitability in the 
fact that female sex hormones facilitate responsiveness 
to interferon. 5,6 Vindictively or naturally testosterone 
promote expression of scavenger receptors found on 
human monocyte-derived macrophages and HepG2 
cell, receptors on which HCV binds resulting in 
harbouring higher HCV loads in males than females. 
7,8.The inhibitory action of 17β-estradiol on release of 
mature virions observed in Huh-7.5 cells transfected 
with viral replicon in culture make females better 
candidates for responding to interferon, for interferon 
also interferes with viral replication. 9 Progesterone 
ceases to produce same inhibitory impact in the similar 
culture. 9 Chronic HCV activities are found to be 
reduced in pregnancy predilection somewhat bias of 
HCV in favour of females by sparing them. 10 In 
contrary to previous researches, Watashi et al. 
reported HCV replication is correlated with oestrogen 
receptor-α activity, making females more vulnerable 
for harbouring HCV loads.11  
The available literature on the correlation of gender 
with HCV load was negligible in Pakistan while with 
that of interferon response was scanty. This study can 
lead to an interesting probe in Pakistan, where 
previous International researches are not conclusive on 
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a single point and develop contradictory inferences 
regarding HCV load with gender. The antagonism 
observed in different research studies procrastinate 
ambiguity regarding gender bias which some 
researches hold with HCV load for many infer that 
males are more prone to retain higher HCV loads than 
females. Some propose gender bias for HCV load to 
response to therapies and others base it on inherent 
defence in female gender. The correlation of gender 
with HCV load has vital role to play in determining 
effective therapeutic approach in different genders 
apart from entirely divergent prognostic interventions. 
While studies label females as better interferon 
responders, our study will try to predict the righteous 
gender for interferon therapy conventionally while 
giving novice therapeutic  approach to the gender 
lagging behind in interferon response. This could also 
make one of the genders once exposed to HCV as 
more preferred subject of early interventions and 
investigations to prevent advanced HCV 
complications like cirrhosis and HCC.  
The objective of our study was to compare the mean 
levels of quantitative PCR (RNA) of males and female 
Hepatitis C positive patients and also to compare 
responsiveness towards interferon therapy between 
males and females presenting to Liver Centre, Holy 
Family Hospital Rawalpindi. 
Alternate hypothesis of our study were 
i) Mean levels of quantitative PCR (RNA) levels 
are not the same in male and female 
Hepatitis C patients. 
ii)  Females are better responders to interferon 
therapy. 
 
Materials and methods 
This cross sectional analytical study was conducted at 
Liver Centre of Holy Family Hospital, Rawalpindi, 
Pakistan. Study population comprised of chronic 
Hepatitis C patients with confirmed diagnosis, 
admitted in Liver Centre of Holy Family Hospital, 
Rawalpindi from February 2015 to January 2016.  
According to reference values given in parent study 
with power of test 80% and level of significance 5 %, 
the minimally required sample size for our study was 
calculated to be 204 with 102 males and 102 females. 12 
From all the registered patients at the Liver Centre, 
Simple Random Sampling technique was applied, 
using SPSS generated random number list. All the 
relevant information from the records of the selected 
patients was deduced after their verbal informed 
consent and was recorded in the structured checklists 
formulated for this study. All the information 
regarding, gender, HCV load (qualitative PCR assay), 
interferon conventional therapeutic response of 
patients, past surgical history and blood transfusion 
history was collected. Viral load corresponds to the 
amount of the viruses one has flowing in his blood in a 
specific volume (usually 1millimeter=1cubic 
centimetre). The amount of hepatitis C genetic 
substance found in the blood refers to number of 
viruses circulating in the blood. It can also be 
perceived as viral equivalents. 
Quantitative HCV loads are the figures of the 
measured HCV viruses in the blood. Following 
reference ranges for ascending HCV loads were used 
in the study: 
Low               200,000 to 1,000,000 IU/L 
Medium       1,000000 to 5,000,000 IU/L 
High              5,000,000 to 25,000,000 IU/L 
Very high     above 25,000,000 IU/L 
Pegylated interferon alfa – 2a is an antiviral drug, 
which has a longer half-life than innate human and 
native interferon via its pegylation.  All Patients 
included had confirmed diagnosis of chronic liver 
disease by anti-HCV core antibodies and chronicity of 
disease with development of complications like ascites, 
cirrhosis etc. All patients were having conventional 
therapy with interferon or had treatments with it. All 
patients with confirmed history and diagnosis of IV 
drug abuse, pregnancy and AIDS were excluded. 
Data entry & analysis was done in SPSS (Statistical 
Package of Social Science) version 22. For numerical 
variables like age and quantitative PCR RNA levels 
mean, mode, range and standard deviation were 
calculated. To compare the mean levels of quantitative 
PCR (RNA) or viral load of male and female patients’ 
independent samples “t” test was applied at 5% level 
of significance. For categorical variables like gender, 
categories of viral load and responsiveness to 
interferon therapy, frequencies and percentages were 
calculated and Pearson’s Chi square test was applied 
to compare the categories of viral load and 
responsiveness in both male and female patients.  A p 
value of < 0.05 was considered statistically significant. 
 
Results 
Based on completion of available samples, 104 males 
and 100 females were included in study. Total 
respondents were 204 which had mean age of 48.33 
years ±11.162 years where median and mode of age 
were 50 years each. Youngest patient was 13 years old 
where the eldest was 80 years old with range 67 years. 
Mean age of females was 48.89 years±11.648 years 
whereas mean age of males was 47.73yrs ±11.53 yrs. 
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Mean Quantitative PCR of all 204 patients was 3.79E6 
±1.517E7 IU (International units) where median was 
6.98E5 IU while mode was 30E3 IU. Minimum PCR 
value was 30 IU whereas highest value was 2E8 IU 
with range of 2.0E8 IU. 
Mean PCR of females was 4.57E6 ±1.998E7 IU where 
mean PCR of males was 3.04E6 ±8296048.199 IU and 
this difference was not statistically significant with a t-
value of 0.71 and p value of 0.473 upon applying 
independent sample’s t test. Overall 17.2% of patients 
amongst all 204 had high, 24.5% had medium, 31.4% 
had low and 27% had very low viral loads. When 
these were compared based on gender, no statistically 
significant difference was observed amongst male and 
female patients with a chi value of 1.01 and p value of 
0.797. Difference is shown in Figure I exhibiting 
categories of viral loads in male and female patients. 
Amongst 204 patients, 48 (23.52%) patients did not 
respond to previous interferon therapy while 68 
(33.33%) did respond, shown in (Table I). When 
gender wise comparison was made between 
responders and non-responders (excluding naive and 
partial responders), amongst 67 males, 31 (46.26%) did 
not respond to the interferon treatment whereas 36 
(53.74%) did respond. Out of 49 female patients, 
17(34.70%) did not respond to treatment while 
32(65.30%) did respond to it, though this difference 
was not statistically significant with a chi value of 1.52 
and a p value of 0.2. 
Table-I Comparison of Treatment Response Of 
Interferon Therapy 
GENDER NAÏVE 
*f (%) 
NON 
RESPONDER 
PARTIAL 
RESPONDER 
RESPONDER TOTAL 
MALES 34 
(32.69%) 
31(29.80%) 3 (2.89%) 36 (34.62%) 104 (100%) 
    
FEMALES  51 
(51.00%) 
17 (17.00%) 0 (0.00%) 32 (32.00%) 100 (100%) 
TOTAL 85 
(41.66%) 
48 (23.53%) 3 (1.48%) 68 (33.33%) 204 (100%) 
*f (%)= frequencies (percentages) 
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Figure I. Comparison Of Hcv Viral Load Based On Gender 
Out of 204 chronically ill HCV patients, only 42 
(20.6%) had positive history of blood transfusion while 
162 (79.4%) having a negative history for the variable.  
Whereupon the gender of the chronically ill HCV 
patients was considered, blood transfusion history was 
positive in 29% females as compared to 13% of males, 
giving a difference to gender predilection of HCV in 
terms of blood transfusion kept as a sacred risk factor. 
Upon applying the Chi Square test the difference was 
highly statistically significant with a p value of 0.00.  
Whereupon in aspect of other risk factor of past 
surgical history, 54% HCV loaded females had a 
positive history in combat with 35% males positive for 
HCV with highly statistically significant difference 
having chi value of 7.7 and the p value of .005. 
 
Discussion 
In our parent study from Guangzhou , China in 2001 
to 2009,12 one of the significant association found in 
previous studies was refuted giving the bias  towards 
the gender probed over in other studies as non-
existent. According to our study, HCV load is 
indiscriminately distributed amongst both genders. 
Our findings are inconsistent with the internationally 
commented results in various foreign studies. 
Moreover the interferon drug responsiveness was 
commented as higher in females than males which was 
consistent with the international studies’ results. 
In the reference study, having .006 as ‘p’ value, HCV 
loads among males were higher than females about 2.5 
times. Of the total population 71.1 % of the HCV 
patients having significant viremia were male 
population in the study while only 28.9% of the HCV 
loaded patients were females. Contrarily, in our study 
group of 204, about 51% were males while 49% were 
females giving no statistical significance upon 
applying Chi Square test with a ‘p’ value of 0.797. 
A study conducted at Ayub Medical College , 
Abbottabad  in 2014 13, response to interferon was 
found to be higher in males i.e., 76.14% compared to 
that with females, i.e., 72.77%, while partial response 
was almost same in both the sexes (88.71% in males 
and 89.93% in females). However, our study had 
contrary results where females emerged as better 
responders with 65.30%  females were responders 
compared to  53.73% responding males . Our study 
contrasted in terms of interferon response with this 
study 13 establishing females as better responders to 
conventional interferon in chronic HCV illness, though 
results are not statistically significant. 
In a study conducted on 100 chronic HCV patients 14, 
with 50 males and 50 females, rate of therapeutic 
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response to conventional interferon was significantly 
higher in women than in men (66.7% vs. 38.2%, P < 
0.05) giving a P value of 0.001 which supported our 
calculations. Hence, giving the same  results with 
females emerging as better interferon responders.  
In a study conducted at a liver centre in Italy 5, 41 out 
of 55 males (74.55%) exhibited virological response to 
interferon while 156 out of 172 females (90.6%) were 
responsive to interferon therapy with statistical 
significance in responsiveness between males and 
females according to a ‘p’ value of 0.006. Our study 
exhibited consistency in term of results, though the 
rates of responsiveness in both males and females are 
not that much higher. In our study at Holy Family 
Hospital Liver Centre about 34.70% females were non 
responders while 53.73% males were non responders 
in contrast to 25.55% non-responder males and 9.4% 
non-responder females in the study 5. Our study 
thereby held similarity with the study mentioned, with 
lesser females with failure to respond as compared to 
males.5   
The strength of our study is that it encompasses 
interferon, the most widely used conventional therapy, 
effectiveness in different genders of patients who have 
developed complications of chronic HCV infection 
apart from screening the prone gender to 
complications which is a sui generis and pioneer 
study, in this regard, in our set up. It instigates new 
researches in this dimension to be undertaken by our 
country specialists. Whereas the frailty it holds is that 
it does not encompass the combined drug regimens 
with interferon effectiveness in different genders as 
well as it does not classifies the female population into 
premenopausal and postmenopausal , and pregnant 
and non-pregnant categories while evaluating the 
gender bias of HCV load distribution and interferon 
responsiveness . Even though the difference in 
treatment is in consistency with the previous 
researches, our methodology did not follow up each 
patients after initiation of treatment and measured the 
responses of treatments once the patients had 
completed the treatment, hence missing the 
information relevant to compliance of patients with 
the treatment and the severity of illness or concurrent 
complications of the disease during treatment period 
that might have affected the outcomes. 
HCV patients should be subjected to high surveillance 
to prevent development of complications irrespective 
of any gender bias for many studies claim males to be 
at high risk for acquiring higher HCV load. Risk 
factors should be surveyed as well and as our study 
claims that blood transfusion is a higher contributing 
factor in females when it comes to harbouring a 
significant HCV load, thereby females having 
undergone blood transfusion and surgeries must be 
monitored more often for HCV development and its 
complications like cirrhosis and HCC. Moreover HCV 
loaded males should be given longer follow ups and 
more effective drug regimens once their interferon 
therapies are initiated as, according to our study, 
females respond better to interferon.  Hence gender is 
not biased when it comes to HCV load, it has equal 
discrepancies but some risk factors as transfusion and 
past surgical history make females slightly at a higher 
risk of being HCV loaded than males but males lag 
behind in therapeutic response. 
 
Conclusion 
Gender did not pose a core value in determining HCV 
loads. The distribution of HCV loads amongst various 
viral load groups were gender independent. Females 
emerged as better responders to conventional 
pegylated 2 alpha interferon therapy than males.  
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